Insilico Medicine Launches Longevity Board for AI Drug Discovery
Cambridge, Massachusetts, USA, April 21, 2026 In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Cambridge, Massachusetts, USA, April 21, 2026 In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has...
